Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026
4.6.2026 15:45:00 EEST | ACCESS Newswire | Press release
LONDON, UK / ACCESS Newswire / June 4, 2026 / The Biotechnology Business Unit of Gedeon Richter Plc. (Richter) is present at this year's European Alliance of Associations for Rheumatology's (EULAR) European Congress of Rheumatology, underlining its role as a growing contributor to biologic therapies in Europe. The company also hosted a satellite symposium on the opening day, as part of its engagement with the rheumatology community.
Richter's presence at EULAR reflects nearly two decades of focused investment following its strategic entry into biotechnology. Today, it operates a fully integrated biosimilars business with a European development and manufacturing network, including facilities in Budapest and Debrecen in Hungary, operations in Germany, and global partnerships supported by over 1,000 biotech professionals.
As part of its scientific program, yesterday Richter hosted the symposium "Prevention, better than treatment - insights on inflammatory joint disease and osteoporosis" chaired by Professor Paul Emery. The session addressed key aspects of disease management, including osteoporosis as an often overlooked dimension of rheumatoid arthritis, presented by Dr. Lothar Seefried, and the role of biologic therapies in achieving remission-driven outcomes, discussed by Professor James Galloway.
"Richter's progress in biosimilars reflects our commitment to making biologic therapies more accessible to patients, while events such as EULAR and collaboration with leading experts remain essential to advancing care" said Dr. Erik Bogsch, Head of the Biotechnology Business Unit at Richter.
Building on its long-term strategy, Richter is establishing a rapidly expanding biosimilar portfolio across rheumatology, immunology, and osteoporosis. The company's portfolio includes the denosumab biosimilars Junod® and Yaxwer®, as well as its newest addition, the tocilizumab biosimilar Tuyory®, strengthening Richter's presence in the treatment of chronic inflammatory conditions such as rheumatoid arthritis. Richter continues to progress its biosimilar pipeline, leveraging both in-house expertise and in-licensing opportunities.
From its early biosimilar entry with Terrosa® to today's broadening portfolio, Richter has consistently focused on developing high-quality biosimilar medicines to established biologics. Biosimilars can support healthcare systems by providing additional treatment options where approved and used in line with local guidance.
Through its active participation at EULAR, Richter reaffirms its commitment to scientific exchange, innovation, and improving patient care across Europe and beyond.
About Richter
Richter aspires to be a global innovator in some key scientific fields, while dedicated to making medicines more accessible worldwide. Founded in 1901, headquartered in Hungary, with a market capitalization of EUR 4.8bn and sales of EUR 2.3bn in 2025, it operates Central Europe's largest R&D hub. Its research drives advances in Neuropsychiatry and Women's Healthcare, while Biotechnology and General Medicines strengthen its affordable treatment portfolio. Committed to sustainable growth, Richter invests in R&D, manufacturing excellence, and digitalization to advance medical innovation. Learn more at www.gedeonrichter.com
For further information:
Media: Zsuzsa Beke +36 20 916 4507
SOURCE: Gedeon Richter Plc.
Gedeon Richter Plc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Three Polaris Projects in Mexico Selected Under the Mixed Development Program9.6.2026 02:40:00 EEST | Press release
TORONTO, ON / ACCESS Newswire / June 8, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") announced that Mexico's Secretary of Energy (Secretaría de Energía, "SENER"), and the Federal Electricity Commission (Comisión Federal de Electricidad, "CFE") have completed the first national competitive selection process under the CFE Mixed Development Program. The process was launched through a Request for Proposals ("RfP") issued in February 2026, with submitted projects evaluated in accordance with the Guidelines for Mixed Development Programs published by SENER in January 2026. On June 5, 2026, CFE and SENER announced that the final award volume exceeded the original target, with approximately 8,000 MW of projects selected for advancement under the program. As part of this award process, Polaris is pleased to announce that all three Polaris-owned projects submitted under the Mixed Development Program have been selected to advance to the final contract negotiation st
GA-ASI Announces Investments in Six Dutch Companies8.6.2026 19:00:00 EEST | Press release
New Slate of Business Partnerships Established Following the Last Blue Magic Netherlands Event SAN DIEGO, CA / ACCESS Newswire / June 8, 2026 / General Atomics Aeronautical Systems, Inc. (GA‑ASI) is deepening its footprint in the Dutch innovation ecosystem, with new investments in six Netherlands-based technology companies through its Blue Magic Netherlands (BMN) venturing initiative. These new partnerships follow the latest BMN event in Eindhoven, a fast-paced, "shark tank"-style forum in which Dutch startups and scaleups pitched breakthrough technologies directly to GA‑ASI decision makers. The most recent edition drew more than 350 attendees from across the country's aerospace, defense, and high-tech communities. Building on the success of prior events, GA‑ASI has selected six Dutch companies for new investment and collaboration. GA-ASI also is increasing its investment in Emergent Swarm, first discovered at BMN 2024. Emergent Swarm is partnering with GA‑ASI to further mature its swa
Media Invitation: Fields Medals and Cutting-Edge Math at ICM 2026 in Philadelphia2.6.2026 21:30:00 EEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / June 2, 2026 / Members of the press are invited to the world's most prestigious mathematics conference, which will take place at the Pennsylvania Convention Center in Philadelphia from July 23 to July 30, 2026. Held every four years, the International Congress of Mathematicians (ICM) includes the announcement of the field's top prizes - including the Fields Medals - as well as top talks from leading mathematicians on cutting-edge developments in the field. Staff reporters and freelance journalists can register to attend the conference free of charge through June 22. Media registration includes access to a press conference with the Fields Medalists and other honorees following their announcement during the July 23 opening ceremony. A press room will also be available during the conference. Discounted hotel room rates are available to attendees. For more information, visit the ICM 2026 website or email icmpressinquiries@simonsfoundation.org. The confe
IXOPAY Launches Payments Intelligence and IXONav, an AI Payments Assistant Built to Unlock Real-Time Insights Across the Payments Journey2.6.2026 07:00:00 EEST | Press release
Company's intelligence layer combines AI-driven analytics with anomaly detection to improve merchant payments optimization, performance and revenue outcomes LEHI, UT / ACCESS Newswire / June 2, 2026 / IXOPAY, the performance layer powering global payments for the agentic era, today announced IXOPAY Payments Intelligence, a unified control center that transforms fragmented payment data into real-time, actionable insights. The company also launched IXONav, a new AI agentic navigator built to unlock key insights at every step in the payments journey. By combining AI-driven analytics, anomaly detection and LLM agents, the platform helps merchants uncover optimization opportunities, improve routing performance, increase authorization rates and reduce per-transaction costs. IXOPAY's no-code payments platform unifies payment orchestration, tokenization, and intelligence, and provides merchants with a configurable infrastructure to optimize their payments performance. The IXOPAY Payments Intel
Clean Air Metals Files Audited Annual Financial Statements for the Year Ended January 31, 20262.6.2026 04:00:00 EEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 1, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its audited consolidated financial statements and management's discussion and analysis for the year ended January 31, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at January 31, 2026 of $36,226,670 Total cash as at January 31, 2026 of $1,133,766 Working capital deficiency as at January 31, 2026 of $2,281,241 Shareholder's equity as at January 31, 2026 of $32,604,804 During the year ended January 31, 2026, the Company incurred $1,190,489 in cost for exploration activities at the TBN project. Early in the year, the Company's management team executed a successful drill program at the Current Deposit to delineate larger ballroom structures. This was followed up by a significant undertaking at the Escape Deposit down plunge, to reassess past MT data and refine drilling targets in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom